Great quarter from ANIP, although I thought that was largely true last quarter too and then the stock sold off hard. Its been a great investment for me so far, but I'm starting to fade this strong move up. Short term its very overbought and so a sell on TA....but I think based on revisions to eps growth in FY26 it could be trading into the low 90s by next year. Still need a little bit more insight into the growth prospects for FY26, but they had a lot of questions on the quarterly call on the growth trajectory of one of their primary revenue generators, Cortrophin gel. Very bullish comments on this from the CEO, imo.
I'd be wary of initiating a position up at these price levels, but I do think there is still some upside.
Market Data 
Markets 
AI
